Pluvicto®▼(lutetium [¹⁷⁷Lu] vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.¹

 

Pluvicto®▼

Pluvicto® is the first and only approved PSMA-targeted radioligand therapy (RLT) in the United Kingdom (UK) and is available to eligible private patients in the UK.¹